5534-13-4

Usage

Uses

Used in Pharmaceutical Industry:
9-fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate is used as a glucocorticoid for its potent anti-inflammatory and immunosuppressive effects. It is particularly effective in treating various inflammatory and autoimmune conditions, such as rheumatoid arthritis, asthma, and allergies.
Used in Dermatological Applications:
In the dermatological field, 9-fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate is used as a topical treatment for various skin conditions, including eczema, psoriasis, and contact dermatitis. Its anti-inflammatory and immunosuppressive properties help to reduce redness, swelling, and itching associated with these conditions.
Used in Ophthalmic Applications:
9-fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate is also used in ophthalmology as an anti-inflammatory agent for treating eye conditions such as uveitis, iritis, and postoperative inflammation following ocular surgery.
Used in Veterinary Medicine:
In veterinary medicine, 9-fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate is used as a glucocorticoid to treat inflammatory and immune-mediated conditions in animals, similar to its applications in human medicine.

InChI:InChI=1/C25H33FO6/c1-5-21(31)32-25(20(30)13-27)14(2)10-18-17-7-6-15-11-16(28)8-9-22(15,3)24(17,26)19(29)12-23(18,25)4/h8-9,11,14,17-19,27,29H,5-7,10,12-13H2,1-4H3/t14-,17-,18-,19-,22-,23-,24-,25-/m0/s1

Upstream product

• 24823-81-2 trimethoxypropane 
• 378-44-9 betamethasone 
• 1062-09-5 Betamethasone 17α,21-ethyl orthopropanoate 
• 5593-20-4 betamethasone dipropionate 

Downstream Products

• 5593-20-4 betamethasone dipropionate 
• 15423-80-0 betamethasone 17-propanoate 21-mesylate 

Relevant academic research and scientific papers

Preparation method of betamethasone 17 alpha-propionate

The invention provides a preparation method of betamethasone 17 alpha-propionate. According to the preparation method, betamethasone is subjected to a reaction with triethyl orthopropionate, the reaction is performed in a tetrahydrofuran solvent, further, p-toluenesulfonic acid is adopted as a catalyst, after the reaction is finished, an aluminum trichloride solution is dropwise added to the samesolvent system directly without discharging, a thermal insulation reaction is performed after the solution is dropwise added, and betamethasone 17 alpha-propionate is obtained with a post-treatment process. According to the preparation method of betamethasone 17 alpha-propionate, preparation process is simplified, yield is increased and purity is improved while the problem that dioxane, dimethylformamide or another solvent is adopted as the reaction solvent of betamethasone 17 alpha-propionate is solved.

A variation of Mattox rearrangement mechanism under alkaline condition

A variation of the Mattox rearrangement, a key degradation pathway under acidic conditions for corticosteroids possessing the 1,3-dihydroxyacetone side chain, has been found to occur for the 17,21-diesters of these corticosteroids but under the alkaline condition. The mechanism of this variation of the original Mattox rearrangement is proposed.

Composition for the topical treatment of poison ivy and other forms of contact dermatitis

Composition for topical administration comprising (a) a corticosteroid, and (b) a drying agent.

CORRELATION BETWEEN METABOLISM OF BETAMETHASONE 17,21-DIPROPIONATE AND ADRENAL HYPERTROPHY IN RAT FETUSES

The effects of metabolites of betamethasone 17,21-dipropionate (BMDP) on the hypothalamo-pituitary-adrenocortical axis were assessed by measurements of adrenal weights, after studying the metabolism of BMDP in vivo and in vitro in pregnant rats and mice.After BMDP was injected intravenously at a dose of 5mg/kg into rats and mice in late stages of pregnancy, it disappeared rapidly from the plasma and brain in both mothers and fetuses while betamethasone 17-propionate (BMP) was detected as the main metabolite followed by betamethasone (BM).In vitro studies demonstrated that BMDP was metabolized to BMP in maternal and fetal tissues (plasma, liver, brain and placenta) of both species.The subcutaneous administration of BMP to rats in the late stages of pregnancy induced adrenal hypertrophy in fetuses, though the adrenals of the mothers became atrophic.In the case of mice, both maternal and fetal adrenals became atrophic.Administration of BM produced adrenal atrophy in mothers and fetuses of both species.The subcutaneous administration of 6β-hydroxybetamethasone 17-propionate (6β-OH-BMP) to rat fetuses in utero produced adrenal hypertrophy and 6β-hydroxybetamethasone (6β-OH-BM) showed no effect.These data suggest that BMP is transferred across the placental barrier to produce marked adrenal hypertrophy in rat fetuses.